VIDEO: ‘Astounding’ DESTINY-Breast03 findings from San Antonio Breast Cancer Symposium
Click Here to Manage Email Alerts
In this video, Sara M. Tolaney, MD, MPH, discusses recent findings from DESTINY-Breast03 that assessed the use of fam-trastuzumab deruxtecan-nxki in previously treated patients with HER2-positive unresectable or metastatic breast cancer.
The findings were presented at this year’s San Antonio Breast Cancer Symposium.
Tolaney, chief of the division of breast oncology at Susan F. Smith Center for Women's Cancers in the Dana Farber Cancer Institute, noted that while previous findings from the study showed that fam-trastuzumab deruxtecan-nxki ([T-DXd]; Enhertu; AstraZeneca, Daiichi Sankyo) resulted in better PFS compared with ado-trastuzumab emtansine ([T-DM1]; Kadcyla; Genentech) when used in a second-line, HER2-positive setting, this update provided “OS data where it actually did reach statistical significance, which I thought was really impressive.”
She added that although the median odds ratio was not reached in either arm of the randomized study, the hazard ratio was significant.
Tolaney said it was “really astounding to see that the PFS for T-DM1 was just over 6 months compared to over 28 months with T-DXd,” in the updated PFS data presented at the meeting.
“It’s really a landslide difference, and it does make you wonder now how T-DXd is going to perform in even earlier line settings — in the first-line HER2-positive setting, for example — and even in the preoperative and post-preoperative setting where there are studies ongoing with T-DXd for HER2-positive disease.”
Collapse
Click Here to Manage Email Alerts